This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In this article we discuss the challenges for manufacturers of therapeutics and diagnostics as they pursue the potential of companion diagnostics. Click below to read the article.
Insight as your ABP backbone Annual Brand Planning (ABP) should not feel like a reinvention exercise every year, particularly for established brands. Instead,...
This study used a consensus-based approach to identify high-impact solutions for reducing racial and ethnic health disparities in lupus. Through a literature...
Last year, Regeneron took to trial its case alleging exclusionary conduct through bundled rebates by competitor Amgen. The jury found for Regeneron, awarding...
CRA is a proud sponsor of Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, 10 tracks and 1500+ attendees from pharma,...
